TLDR
- Moderna stock touched a 52-week high of $192.31 on Wednesday before closing down 0.3%.
- CEO StΓ©phane Bancel told the Bernstein healthcare conference the company has “never been” just a Covid vaccine maker.
- Moderna is leaning on intismeran autogene, a personalized cancer vaccine co-developed with Merck, to prove its mRNA platform works beyond Covid.
- The company raised $2.6 billion in convertible notes and has five approved vaccines on the market.
- New melanoma, lung and pancreatic cancer data from the intismeran program are due at a European oncology meeting in late October.
Moderna stock climbed to a fresh 52-week high of $192.31 on Wednesday. Shares then gave back the gains and closed down 0.3%, even as the broader market slipped.
The move came after CEO StΓ©phane Bancel spoke at Bernstein’s annual healthcare conference. He told the room that Moderna “has never been” a Covid vaccine company. Instead, he called it an mRNA platform company that happened to respond to a pandemic.
Chief Development Officer David Berman backed him up. He said oncology and rare diseases are now central to the company’s identity, not side projects.
It’s a message Moderna has been trying to sell investors for a while. The stock is still far below its mid-2021 peak above $380, when Spikevax was minting record revenue during the height of the pandemic.
Cancer Vaccine Carries the Narrative
The centerpiece of Wednesday’s pitch was intismeran autogene, a personalized cancer vaccine built on Moderna’s mRNA tech and co-developed with Merck. It’s designed to target the specific mutations found in a patient’s own tumor.
Berman called the Phase III melanoma data among the most rigorous immunotherapy results he’s seen. The trial hit both its main goal and a key secondary measure in an early analysis, beating PD-1 therapy alone as an add-on treatment.
That data helped Moderna shares nearly triple in a single session back in August. It’s now the reference point management keeps returning to when explaining why the mRNA platform still has legs.
Executives said intismeran is being tested in nine trials across multiple tumor types, including three Phase III lung cancer studies. Results in kidney and bladder cancer are expected within a year.
Where the Bottleneck Actually Is
Manufacturing was the story during Covid. This time, Moderna says the holdup is hospitals, not factories.
Berman and Bancel said the real challenge is getting hospitals to collect biopsies, process the genetic data, and coordinate treatment fast enough. Moderna and Merck are building implementation teams hospital by hospital to speed that up.
On the money side, Moderna disclosed a $2.6 billion convertible note raise to fund its pipeline. The company also pointed to five approved vaccines already generating revenue, with two more launches planned.
The Merck partnership splits costs and profits 50-50, and management said pricing talks are on hold while the focus stays on generating data and getting through regulatory review.
Beyond oncology, Moderna highlighted its rare disease work, led by a liver-targeted treatment for propionic acidemia with pivotal data expected by the end of 2024. The company is also testing an in vivo CAR-T program for autoimmune disease.
Bancel didn’t oversell intismeran itself. He called it “not our best product,” but said it’s an important first step into oncology.
He framed Moderna’s outlook in five to 10 year terms rather than quarterly results. New data on intismeran in melanoma, pancreatic cancer, and lung cancer is set to be presented at the European Society for Medical Oncology meeting in late October.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions β all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
